GLP‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 10, 2025

Abstract Aims The associations of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and outcomes among patients with obesity according to the presence cardiovascular risk factors (metabolically healthy (MHO) or metabolically unhealthy (MUHO)) remain unclear. We examined GLP‐1RAs mortality adverse events in MHO MUHO. Methods TriNetX network was utilized select a cohort MUHO, use non‐use propensity score matching (1:1). Cardiovascular were identified during follow‐up. Results A total 2 983 151 (512 434 470 717 MUHO) included study. Among these, 416 713 (13.9%) GLP‐1RA users. After matching, MUHO associated significantly lower (HR 0.580 [95% CI, 0.566–0.595]), ischemic stroke 0.921 [0.890–0.953]), AF 0.913 [0.888–0.938]) hospitalization for HF 0.925 [0.900–0.949]) follow‐up compared GLP‐1RA. Patients had markedly clinical than those trend towards seen MHO. There no statistical interaction patients. Conclusions rates Similar but non‐statistically significant trends

Language: Английский

---

Compound J27 alleviates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease by targeting JNK

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 154, P. 114570 - 114570

Published: April 7, 2025

Language: Английский

---

The potential role of adipokines and hepatokines in age-related ocular diseases

Metabolism Open, Journal Year: 2025, Volume and Issue: unknown, P. 100365 - 100365

Published: April 1, 2025

Age-related ocular diseases, including diabetic retinopathy (DR), age-related macular degeneration (AMD), cataract and glaucoma may lead to visual impairment even blindness. Metabolic such as obesity metabolic dysfunction-associated steatotic liver disease (MASLD) have emerged potential risk factors of especially DR. Visceral adiposity has been associated with increased DR AMD in most clinical studies, although body mass index to-date provided conflicting association AMD. In addition, is recognized a factor glaucoma. Similarly obesity, MASLD appears be patients type 1 diabetes mellitus, but probably not those 2 mellitus. A positive between AMD, supported by limited evidence to-date, thus needing further investigation. Altered secretion patterns adipokines (adiponectin, leptin, lipocalin-2, resistin) hepatokines [adropin, fetuin-A, fibroblast growth (FGF)-21, retinol binding protein (RBP)-4] seem disrupt homeostasis contribute the development diseases context MASLD. this regard, novel adipokine-based hepatokine-based therapies added treatment options for future. This narrative review aimed summarize on interconnection specific focus roles mediators these associations.

Language: Английский

---

Refining metabolic syndrome trait definitions in MASLD: A call for greater precision in cardiovascular risk assessment

Liver International, Journal Year: 2024, Volume and Issue: 44(12), P. 3290 - 3291

Published: Oct. 18, 2024

Data sharing is not applicable to this article as no data sets were generated or analysed during the current study.

Language: Английский

---